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Background: Aiming at the enhancement of food products' nutritional and health value, the incorporation of
nutraceuticals has attracted increasing interest in the last years. However, they often exhibit low water solubility
and stability, limiting their direct incorporation into food products. Also, they show very low bioavailability due
to limited bioaccessibility, poor absorption and/or chemical transformation within the gastrointestinal tract.
This renders their health beneﬁts extremely diﬃcult to be realized by the consumers.
Scope and approach: In the present review the recent innovations regarding the formulation and design of bio-
based micro and nano-delivery systems to encapsulate nutraceuticals is discussed; it also gives an overview of the
challenges associated to their development; and highlights some strategies to enhance nutraceuticals' bioa-
vailability. An insight about delivery systems' potential toxicity (in particular at nano-scale) is also provided.
Key ﬁndings and conclusions: Recent developments in the design of bio-based delivery systems oﬀer the possi-
bility of stabilizing and enhancing nutraceuticals' functionality within food products. In fact, diﬀerent strategies
can be used to enhance nutraceuticals' bioavailability: i) nano-delivery systems, besides showing a huge po-
tential for the protection of valuable nutraceuticals during food processing/digestion, can be used to increase
their bioavailability; ii) absorption enhancement technologies have been successfully used to increase nu-
traceuticals' membrane permeation; and iii) excipient foods have been shown to improve nutraceuticals' bio-
logical activity. However, the application of these enabling technologies to food is hindered by very pertinent
issues that can be summarized in the eﬀective preservation/maximization of the nutraceuticals' bioactivity and
safety, once inside the human body.
1. Introduction
In the age of chronic diseases (obesity, Type II diabetes and cardi-
ovascular diseases) and rising number of elderly people, bioactive
compounds that exhibit health-promoting eﬀects are receiving in-
creasing attention. Since the strong link between dietary habits and
health has been established, food, in addition of being a good source of
nutrients with good sensory appeal, also needs to be beneﬁcial to the
health and well-being of the consumers. However, in the modern life-
style it could be diﬃcult to ingest all of the nutrients needed to main-
tain normal body functions or promote good health. The incorporation
of nutraceuticals in food products provides a simple way of developing
novel functional foods. In fact, there is an increasing interest in the
development of functional foods/beverages enriched with diﬀerent
nutraceuticals. Nutraceuticals can be deﬁned as nutritional components
that provide therapeutic or physiological beneﬁts beyond the basic
nutritional needs and include a wide range of compounds such as
bioactive peptides, phenolic compounds, carotenoids, lipids, vitamins,
etc. (Ting, Jiang, Ho, & Huang, 2014). However, the eﬀectiveness of
nutraceuticals in providing therapeutic or physiologic beneﬁts greatly
depends on preserving their bioavailability, deﬁned as the fraction of an
ingested compound that is absorbed and available for physiological
functions (i.e. reaches the systemic circulation in an active form) (Ting
et al., 2014). Diﬀerent factors can compromise the bioavailability of a
compound, including an insuﬃcient gastric residence time, low per-
meability and/or solubility within the gastrointestinal (GI) tract and
instability during food processing/storage or in GI tract (Leonard,
2000). In fact, most of nutraceuticals are unlikely to provide the in-
tended bioactive properties without the use of an appropriate delivery
system. This system should be designed to overcome the speciﬁc factors
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aﬀecting the loaded nutraceutical functionality. Carotenoids, vitamins,
fatty acids, polyphenols, bioactive peptides, phytosterols, ﬁbers and
essential minerals are some examples of nutraceuticals with claimed
biological activity that can beneﬁt from incorporation into delivery
systems (Table 1).
The main challenges of incorporating nutraceuticals such as β-car-
otene, curcumin, vitamins A, D, E and K in food products are their
chemical instability during food processing/storage (e.g. sensibility to
light, oxygen, heat) or within GI tract (e.g. easily degraded by enzymes
and/or pH), their low water solubility and low bioavailability. All these
factors can aﬀect nutraceuticals' functionality, and consequently, their
health beneﬁts may not be recognized even when ingested in high
amounts. Furthermore, when directly incorporated in food products,
nutraceuticals with unpleasant sensory properties (e.g. polyunsaturated
fatty acids) can negatively aﬀect foods' properties and shelf-life.
Alternatively, some of those compounds (e.g. vitamin C) can have un-
desirable interactions with other food components, negatively aﬀecting
foods' appearance, texture, mouthfeel, stability and bioavailability of
important components. Consequently, encapsulation of nutraceuticals
is often required to i) protect them against adverse external factors; ii)
allow their incorporation into food products (e.g. increase the lipophilic
compounds' solubility/dispensability in water-based environments), iii)
mask any oﬀ-ﬂavors; iv) allow their controlled release; and v) preserve/
maximize their functional properties, i.e. to ensure that they are
maintained in their native bioactive form until they reach the site of
action. Therefore, delivery systems at micro and nano-scale have at-
tracted considerable interest worldwide over the past years. Also, in
recent years, diﬀerent strategies have been used and signiﬁcant ad-
vances have been made in the area of delivery systems to enhance the
bioavailability and consequently, nutraceuticals' eﬃcacy.
This work presents a comprehensive state-of-the-art review of the
recent advances in the development of micro and nano-scale delivery
systems to improve the bioavailability of nutraceuticals, from their
formulation/design to the evaluation of their eﬃcacy. Potential risks
that may arise from their use (in particular at nano-scale) will be also
addressed.
2. Formulation and design of delivery systems for nutraceuticals
The successful development of delivery systems for nutraceuticals
requires the knowledge of their properties and the use of adequate
materials and production techniques. In fact, the choice of the adequate
encapsulation procedure is a key step once many nutraceuticals are
sensitive to heat and to high temperature during the encapsulation
process, which could cause loss of their bioactivity.
The design of delivery systems for nutraceuticals that have adequate
physical and chemical stability as well as food-grade status, cost ef-
fectiveness and technological feasibility can involve numerous chal-
lenges. Moreover, to obtain a satisfactory bioavailability for such nu-
traceuticals is even a more challenging task.
2.1. Desirable characteristics of delivery systems
Being one of the delivery systems' main goals the improvement of
nutraceuticals' bioavailability, those should be developed to promote
nutraceuticals' aqueous solubility, adequate residence time in the GI
tract, absorption across the intestinal line and stability to changing
physiological environments (Ting et al., 2014). During the development
or selection of a delivery system, it is important and useful to consider
some parameters. The most relevant parameters are summarized in
Fig. 1 and brieﬂy described below:
2.1.1. Food grade status
In contrast to pharmaceutical products, the delivery systems applied
in food products cannot be composed of synthetic chemical polymers
due to the side eﬀects that these can cause and due to the fact of being
integrated in foods, there is no control over the amounts that consumers
may wish to intake. Therefore, regulatory requirements also oﬀer
challenges to the development of delivery systems for nutraceuticals,
once only food grade materials must be used for encapsulation or as
core ingredients. These materials can be obtained from natural sources
(i.e. bio-based materials), which is the case of proteins, starch, lipids,
gums and cellulosic materials, or can be materials with Generally
Recognized as Safe (GRAS) status such as cyclodextrins, low-molecular
weight emulsiﬁers (e.g. Tweens) and mineral salts (Augustin &
Sanguansri, 2008). Moreover, the processing operations must also have
regulatory approval in the country where the food will be sold
(McClements, 2012a). Diﬀerent countries have diﬀerent regulations, for
example the main governmental agencies regulating food safety are the
European Food Safety Authority (EFSA) in Europe and the Food and
Drug Administration (FDA) in the USA.
2.1.2. Protection of the encapsulated nutraceutical
Delivery systems should be designed to protect nutraceuticals
during processing, storage and transport from adverse factors such as
undesirable interactions with other food ingredients, pH, light, tem-
perature or oxygen. Furthermore, these systems should also protect the
nutraceuticals from the severe GI environment (e.g. high activity of
digestive enzymes and harsh acidic conditions in stomach)
(McClements, Decker, Park, & Weiss, 2009).
2.1.3. Compatibility with the food matrix
Food matrix is the ﬁrst and major factor that aﬀects the biological
fate of the encapsulated nutraceutical. For example, the interactions
between mixed micelles and compounds of the partially digested food
matrix can provoke changes in the properties of the mixed micelles and
alter the digestion and absorption of the nutraceuticals encapsulated
inside them (Yao, Xiao, & McClements, 2014). Additionally, delivery
systems should be compatible with the food matrix, not aﬀecting the
properties of the food product (e.g. aroma, taste, appearance and tex-
ture). Delivery systems can be incorporated within diﬀerent matrices: i)
suspended in aqueous solution to be incorporated in beverages and
drinks, ii) trapped inside a biopolymer matrix for incorporation in
desserts, yogurts and sauces or iii) stuck within a solid matrix for in-
corporation in powders and cereal products (Yao et al., 2014). In the
case of clear beverages, it is possible to use for example, nanoemulsions
because the particles are so small that they do not strongly disperse the
light (McClements et al., 2009).
2.1.4. Controlled release capacity
Another desirable characteristic is the controlled release ability,
which consists in releasing the encapsulated compound with a speciﬁc
concentration/time proﬁle at the desirable site of action. The release
Fig. 1. Main desirable characteristics of delivery systems for food applications.
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process may have several proﬁles such as (McClements, 2012a):
i) Burst release – quick release of most of the encapsulated com-
pound in a short time;
ii) Sustained release – extended release of the encapsulated com-
pound at a constant rate;
iii) Triggered release – the encapsulated compound is released in re-
action to a speciﬁc environmental stimulus such as pH, ionic
strength, enzyme activity or temperature;
iv) Targeted release – the encapsulated compound is released in a
speciﬁc location of the GI tract (i.e. mouth, stomach, small intestine
or colon).
One of the main challenge of designing delivery systems is to have
the capacity to release the nutraceutical when the system is triggered
through an external factor such as pH, moisture, enzymes, temperature
or shear and at the same time, protect the nutraceutical from other
factors until it is released in the site of action (McClements & Li, 2010).
Controlled release of a desirable ﬂavor or release of food ingredients
at an appropriate time during processing or storage are some examples
of applications of controlled release of encapsulated compounds
(Augustin & Sanguansri, 2012, pp. 19–48).
2.1.5. High loading capacity
Delivery systems must have the highest loading capacity possible
and must retain eﬀectively the encapsulated compound until it reaches
a speciﬁc site of action (McClements, 2012a; McClements et al., 2009).
The loading capacity (LC) is a parameter that measures the capacity of a
delivery system to encapsulate the bioactive compound. This parameter
is determined through the mass of encapsulated material (ME) per unit
mass of carrier material (MC) (McClements et al., 2009):
=LC M
M
E
C (1)
The loading capacity is dependent on the bioactive compound
properties and on the encapsulation material used, such as chemical
nature, molecular weight, polarity and volatility of the bioactive com-
pound and its interactions with the food matrix (Augustin & Hemar,
2009).
2.1.6. Bioavailability
Chemical instability during digestion, poor solubility in GI ﬂuids,
low intestinal absorption or ﬁrst-pass metabolism are some common
issues that need to be avoided to increase the nutraceuticals' bioavail-
ability (Yao, McClements, & Xiao, 2015). Furthermore, the bioavail-
ability is aﬀected by the materials used to encapsulate and their phy-
sical state, the encapsulation vehicle and the surrounding food matrix
(Livney, 2015).
2.2. Encapsulating materials
A key step in the delivery systems' development is the selection of
the encapsulating materials, once it will largely inﬂuence the en-
capsulation eﬃciency and delivery systems' stability (Faridi Esfanjani,
Assadpour, & Jafari, 2018). However, this is also a key challenge in
designing food grade delivery systems for nutraceuticals due to the
limited choice of materials that can be used in the formulation. As
previously mentioned, most of the delivery systems developed for
pharmaceutical applications use synthetic components that cannot be
applied to food products due to its potential negative eﬀects upon
chronic consumption (Ting et al., 2014). So it is important to design
delivery systems with bio-based ingredients, biocompatible with food
products and non-toxic for human consumption (Dima, Dima, &
Iordăchescu, 2015). However, some disadvantages of the utilization of
bio-based food ingredients are the diﬀerence in their properties due to
the conditions and processes used for their isolation and the quality and
composition of initial source (Augustin & Sanguansri, 2012, pp. 19–48).
Furthermore, encapsulating materials should have low viscosity, good
Table 2
Most commonly used bio-based encapsulating materials.
Encapsulating material Examples Attractive characteristics References
Polysaccharides Starch Inexpensive; easily available; form glassy solids after dehydration (Panyoyai, Shanks, & Kasapis, 2017)
Chitosan Abundant resource; cationic; antimicrobial; mucoadhesive; natural
swelling-deswelling behavior at diﬀerent pHs; permeation enhancing
eﬀect
(Sotelo-Boyás, Correa-Pacheco, Bautista-
Baños, & Corona-Rangel, 2017)
Alginate Anionic; mucoadhesive; gelation properties (Paques, van der Linden, van Rijn, & Sagis,
2014)
Carrageenan Anionic; gelling and ﬁlm-forming capacities (Li, Ni, Shao, & Mao, 2014)
Pectin Anionic; gelation and emulsiﬁcation properties; anti-oxidative eﬀect (Noh et al., 2018)
Proteins β-lactoglobulin Inexpensive; ability to form gels; antioxidant activity; resistant to
gastric digestion
(Madalena et al., 2016)
Sodium Caseinate Emulsiﬁcation and gelation properties (Montes de Oca-Ávalos, Candal, &
Herrera, 2017)
Lactoferrin Antibacterial; antiviral; immunomodulatory capacity; high iron
binding capacity; high isoelectric point
(Martins et al., 2016)
Zein Ability to self-assemble; insolubility in aqueous conditions; resistance
to gastric digestion
(Zhang, Cui et al., 2016)
Lipids Long chain triglycerides (LCT)
(e.g. corn oil)
Increase bioaccessibility of lipophilic bioactive compounds (Qian, Decker, Xiao, & McClements, 2012)
Medium chain triglycerides
(MCT) (e.g. Miglyol)
Neutral ﬂavor proﬁle (Walker, Gumus, Decker, & McClements,
2017)
Flavor oils (e.g. lemon oil) Strong antimicrobial and antioxidant activities; mask oﬀ-ﬂavors;
typically present low rates and extents of digestion
(Walker et al., 2017)
Low molecular
surfactants
Lecithin Strong emulsifying agent; permeation enhancing eﬀect (Klang & Valenta, 2011)
Sugar esters Good taste and aroma proﬁle; capacity to form diﬀerent colloidal
structures depending on system composition and temperature
(Rao & McClements, 2011)
Ramnolipids Surface active properties; anionic character under appropriate pH
conditions; good stability when heated
(Bai & McClements, 2016)
Quillaja saponin Excellent emulsifying properties; pharmaceutical eﬀects, including
antitumor and antimicrobial activities
(Chung, Sher, Rousset, Decker, &
McClements, 2017)
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ﬁlm forming capacity, barrier and gelling properties and neutral odor
and taste (Augustin & Sanguansri, 2008). Bio-based encapsulating
materials such as polysaccharides, proteins, lipids and low molecular
surfactants have been widely used as encapsulating materials due to
their biodegradability, biocompatibility and non-toxicity. Some ex-
amples of bio-based encapsulating materials, as well as their particular
characteristics that makes them attractive candidates to be used as
encapsulation materials can be found in Table 2.
Polysaccharides are the most used biopolymers in encapsulation of
nutraceuticals for food applications. Polysaccharides can be applied in
the formation of the delivery systems with diﬀerent functions, for ex-
ample as wall material in spray drying microcapsules or as structured-
layered oil-in-water (O/W) interfaces in emulsions. Hydrophobic in-
teractions, hydrogen bonds, van der Waals forces and ionic interactions
are the main interactions established between polysaccharides and
nutraceuticals. Nutraceuticals' release depends mainly on the hydrolysis
of the glycosidic linkages of the polysaccharides (de Vos, Faas,
Spasojevic, & Sikkema, 2010). When polysaccharides are subjected to
environmental alterations such as pH, ionic strength, temperature or
solvent composition, they may undergo transition to diﬀerent ag-
gregation states and diﬀerent conformations.
The incorporation of nutraceuticals within proteins has been also
widely studied. This can occur using molecular complexes (e.g. β-lac-
toglobulin), self-assembled structures (e.g. casein micelles) or poly-
meric gel particles. The latter can be formed through cation-induced
gelation (e.g. soy protein isolate), enzymatic (e.g. trans-glutaminase)
and chemical cross-linking of gels (e.g. glutaraldehyde) (Shutava et al.,
2009). The main interactions responsible for the association between
nutraceuticals and protein complexes and their respective conformation
are hydrophobic and electrostatic interactions, van der Waals forces,
covalent bindings and hydrogen bonds (Oehlke et al., 2014).
Due to their self-assembly capabilities, lipids are also suitable for
incorporation of sensitive molecules, to hide ﬂavors and to control the
release of the encapsulated molecules (McClements et al., 2009). Lipid
carriers can also improve the nutraceuticals' solubilization in the GI
tract, because they have the ability to stimulate the secretion of en-
dogenous biliary-derived solubilizing components including bile salts
and phospholipids (Porter, Trevaskis, & Charman, 2007).
Surfactants, molecules composed by a hydrophilic “head” group and
a lipophilic “tail” group, can spontaneously form micelles, reverse mi-
celles, bilayers and vesicles, at high concentrations. Besides that, they
can organize in diﬀerent liquid crystalline structures such as lamellar,
hexagonal and reversed hexagonal phases (McClements et al., 2009).
Molecular structure characteristics of surfactants and the physico-
chemical environment where they operate determine their functional
properties.
2.3. Delivery systems design
In order to design a delivery system suitable for a speciﬁc nu-
traceutical, generally, tailor made approach should be followed, de-
pending on nutraceuticals' physicochemical properties (e.g. solubility,
chemical interactions and stability) and on the ﬁnal application (e.g.
amount of nutraceutical required, storage conditions, type of food
product and its shelf-life) (Aditya, Espinosa, & Norton, 2017). Also,
there are other important features to take into consideration, such as
optimum nutraceutical concentration, release mechanism and ﬁnal
particle size and density (Faridi Esfanjani & Jafari, 2016).
Delivery systems for food applications can be divided in two groups:
i) lipid and surfactant-based carriers, which include emulsions, lipo-
somes, solid lipid particles, nanostructured lipid carriers and self-dis-
persing lipid formulations and ii) biopolymer-based carriers (i.e. poly-
saccharide and protein-based carriers), which include hydrogels,
protein-polysaccharide complex and polymeric micelles (Fig. 2). The
main characteristics, as well as the advantages and limitations of the
most important delivery systems for food applications are brieﬂy
described below.
2.3.1. Emulsions
Emulsions can be O/W or water-in-oil (W/O) and liquid in liquid or
liquid in solid. The droplet size and emulsion stability are dependent on
the oil type and composition, the surfactant/oil ratio and co-solvents or
co-solutes used. Lipids, low molecular weight surfactants, proteins and
polysaccharides are the main encapsulating agents used (Livney, 2015).
There has been an increasing interest in colloidal delivery systems
based on microemulsions and nanoemulsions because they can be easily
produced from food-grade ingredients using processing operations such
as mixing, shearing and homogenization. These two systems present
many structural similarities, but there are also some important diﬀer-
ences between them. A nanoemulsion can be deﬁned as a thermo-
dynamically unstable colloidal dispersion consisting of two immiscible
liquids, with one of the liquids being dispersed as small spherical dro-
plets (r < 100 nm) in the other liquid, whereas, microemulsions refer
to a thermodynamically stable colloidal dispersion consisting of small
spheroid particles (comprised of oil, surfactant, and possibly co-sur-
factant) dispersed within an aqueous medium (McClements, 2012b).
Microemulsions tend to appear either transparent or only slightly
turbid, have high solubilization capacity for lipophilic compounds, and
are easy to prepare (usually easier than nanoemulsions) and scale up for
commercial applications. However, there is usually a need to use high
amounts of surfactants (generally much higher comparing to nanoe-
mulsions), which could result in toxic eﬀects (Augustin & Hemar,
2009). In fact, microemulsions used in food industry face limitations
mainly due to the restrictions in surfactants' use – there are only a
limited number of food-grade surfactants available for stabilizing these
systems (Chatzidaki, Mitsou, Yaghmur, Xenakis, & Papadimitriou,
2015).
Nanoemulsions may be produced through self-emulsiﬁcation
methods or high pressure homogenization (Dima et al., 2015; Livney,
2015). The principal advantages of this delivery system are the pro-
duction of optically transparent and kinetically stable emulsions, pos-
sibility to control the droplet size, relatively easy manufacturing and
fast absorption upon oral administration. However, it must be taken
into consideration that surfactant amount aﬀects nanoemulsion dro-
plets stabilization and size. Additionally, the use of excessive surfac-
tants may cause toxic eﬀects (Shin, Kim, & Park, 2015).
Emulsions' droplet size has been shown to inﬂuence emulsions'
stability. For example, the eﬀect of droplet size on emulsions' de-
gradation has been investigated by encapsulating lycopene-enriched
tomato extract. The authors used the emulsiﬁcation-evaporation
method and tested diﬀerent parameters of homogenization (i.e. pres-
sure and number of cycles) and obtained nanoemulsions with droplet
diameters between 96 nm and 286 nm and ζ-potential between
−33mV and −42mV, which demonstrated good stability. Regarding
to lycopene emulsions degradation, it was observed that droplets with
smaller size have better protection against the environment and de-
gradative factors (Ha et al., 2015). Other authors developed food grade
conventional emulsions (size of 1285 μm) and nanoemulsions (size of
277 nm) encapsulating vitamin E and they showed that nanoemulsion
formulation increased the emulsions stability when compared to the
conventional emulsion (Parthasarathi, Muthukumar, &
Anandharamakrishnan, 2016).
Emulsions are also able to encapsulate more than one nutraceutical
in the same structure. Mucoadhesive nanoemulsions based on hya-
luronic acid have been developed for co-encapsulating two polyphenols
(resveratrol and curcumin). These nanoemulsions showed to preserve
the polyphenols' antioxidant ability and protect them from degradation
(Nasr, 2016).
2.3.2. Liposomes
Liposomes, sphere-shaped vesicles, are constituted by one (uni-
lamellar) or more (multilamellar) bilayers of lipids that can incorporate
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hydrophilic and lipophilic nutraceuticals. Phospholipids from eggs, soy
and milk are the most used materials for liposome production.
Liposomes can also be produced by non-ionic surfactants, known as
niosomes (Dima et al., 2015).
These systems can be produced by detergent depletion, membrane
extrusion, lipid layer hydration, high pressure homogenization, ethanol
injection method, sonication, reverse phase evaporation and micro-
ﬂuidization (Augustin & Hemar, 2009; Dima et al., 2015). The selection
of the most appropriate production method depends on type of lipo-
somes, phospholipid properties, nutraceutical properties and the re-
lationship between phospholipids and dispersion medium. For instance,
a study has been conducted to evaluate plant sterols encapsulation in
liposomes composed by soy phospholipids through diﬀerent methods
(Alexander, Acero Lopez, Fang, & Corredig, 2012). It has been shown
that the incorporation of plant sterols increased the liposomes' particle
size and their encapsulation eﬃciency. Furthermore, it was concluded
that the preparation methodology may interfere with liposomes' prop-
erties. Ethanol method (in which phospholipids and plant sterols are
mixed with ethanol at room temperature and then heated) presented
the highest encapsulation eﬃciency for liposomes with oil soluble
sterols and better stability to storage and dilution. Other authors de-
veloped diﬀerent vesicular systems to deliver baicalin, a bioactive ﬂa-
vonoid with various pharmacological activities. Results revealed that
all vesicular systems, including liposomes, are promising vehicles for
baicalin in vitro stabilization, sterilization endurance, safety and ocular
pharmacokinetic (Ashraf, Nasr, Nebsen, Said, & Sammour, 2018).
Some advantages of liposomes are biocompatibility,
biodegradability, low toxicity and multi-compounds encapsulation.
However, they have poor storage stability, low encapsulation eﬃ-
ciency, short release time and sensitivity to external factors such as
light, temperature and oxygen (Dima et al., 2015; Shin et al., 2015).
The low stability of liposomes can be circumvented, for example, by the
addition of a coating. Salmon protein hydrolysates have been en-
capsulated in liposomes composed of milk fat globule membrane
phospholipids coated with chitosan using diﬀerent phospholipids and
chitosan concentrations (Li, Paulson, & Gill, 2015). Uncoated liposomes
exhibited diﬀerent sizes depending on phospholipids' concentration,
and an extensive aggregation. However, they presented uniform dis-
tribution size and similar ζ-potential. Regarding coated liposomes, it
was observed that for higher chitosan concentrations, the particles
presented similar size regardless of the phospholipids' concentration
(broad size distribution), and positive values of ζ-potential. Compara-
tively to the uncoated liposomes, coated liposomes showed higher en-
capsulation eﬃciency, stability and lower release in simulated-gastric-
ﬂuids and simulated-intestinal-ﬂuid.
2.3.3. Solid lipid particles (SLPs)
SLPs are composed by lipid droplets that are fully crystallized and
have an organized crystalline structure with the bioactive components
accommodated within the lipid matrix (Katouzian, Faridi Esfanjani,
Jafari, & Akhavan, 2017). The most used lipids are fatty acids, glycer-
ides, paraﬃn, triacylglycerol and waxes. SLPs present several ad-
vantages such as controlled and targeted release, good stability, good
biodegradability and biocompatibility, high loading capacity and low
Fig. 2. Micro- and nano-delivery systems that can be used to encapsulate nutraceuticals.
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cost. However, they present low loading capacity for core materials
with limited solubility in melted lipids, high water content and during
storage, the core can be expelled after liquid-to-solid phase transition.
They can be produced by hot or cold homogenization (Shin et al.,
2015).
The incorporation of nutraceuticals into solid lipid nanoparticles
(SLNs) can be divided in three diﬀerent models (Fathi, Mozafari, &
Mohebbi, 2012; Ramteke, Joshi, & Dhole, 2012):
i) Homogeneous matrix model: also known as solid solution model,
the nutraceutical is present in amorphous clusters or is molecularly
dispersed. It is achieved when cold homogenization method is used
and when highly lipophilic compounds are incorporated in SLNs
without surfactants following hot homogenization method. In the
cold homogenization technique, the nutraceutical is dispersed in
molecularly dispersed form in bulk of melted lipid, then the ap-
plication of the mechanical force of high pressure homogenization
results in the breakdown of molecular form to nanoparticles having
the homogeneous matrix structure. The release process in this
model is based in the dissolution mechanism;
ii) Bioactive-enriched shell: the lipid core is enclosed by a nu-
traceutical-enriched outer shell. Upon cooling, the lipid precipitates
ﬁrst, forming a solid lipid core due to phase separation. Also, the
nutraceutical re-partitions into the remaining liquid phase, re-
sulting in nutraceutical concentration in SLN outer shell. A burst
release behavior is observed is this case;
iii) Bioactive-enriched core: it is obtained when the nutraceutical
dissolves in the melted lipid at or close to its saturation. When the
melted lipid containing the nutraceutical is cooled, supersaturation
of the nutraceutical in the lipid occurs, resulting in the nu-
traceutical precipitation prior to lipid precipitation. Further cooling
will lead to the precipitation of the lipid surrounding the nu-
traceutical enriched core (i.e. as a membrane). In this case, a con-
trolled release regulated by Fick's law of diﬀusion is promoted.
The selection of lipids for the production of SLPs must take into
account the solubility of the nutraceuticals in order to ensure good
encapsulation eﬃciency and loading capacity, biodegradability, di-
gestibility and lipid chemical and thermal stability (Dima et al., 2015).
Also, the type of surfactant absorbed on the oil-water interface and the
use of diﬀerent mixtures of lipids strongly aﬀects SLPs chemical and
physical stabilities. In a recent study, the physicochemical stability of β-
carotene has been improved by encapsulating this nutraceutical into
SLNs containing palmitic acid and corn oil, stabilized by whey protein
isolate (WPI). In this case, palmitic acid crystals covered the surface of
the oil droplets and formed a solid shell to protect the encapsulated β-
carotene. The addition of corn oil in combination with palmitic acid
decreased the probability of β-carotene exclusion from the solid matrix
to the surface of the SLNs, and the WPI was able to increase the β-
carotene oxidative stability. This system showed a high stability against
diﬀerent harsh conditions (Mehrad, Ravanfar, Licker, Regenstein, &
Abbaspourrad, 2018).
2.3.4. Nanostructured lipid carriers (NLCs)
Some authors consider NLCs derived from O/W nanoemulsions
(Tamjidi, Shahedi, Varshosaz, & Nasirpour, 2013) and others a mod-
iﬁed version of SLNs (Shin et al., 2015). NLCs are nanostructures where
the lipidic phase is composed by liquid-lipid and solid-lipid mixtures at
room temperature. This system was developed essentially to overcome
the limitations of SLNs; indeed, the mainly advantages of this system
are higher encapsulation eﬃciency, loading capacity, physical stability,
control release, low toxicity, biodegradability and bioavailability (Shin
et al., 2015; Tamjidi et al., 2013). Due to these attractive character-
istics, in the recent years there has been as increasing interest in NLCs
for encapsulation of nutraceuticals. Rutin-loaded NLCs have been pro-
duced using cacao butter, oleic acid and Tween 80 through high shear
rate homogenization and their incorporation in food models was eval-
uated. The authors observed that particles' size increased between
77 nm and 96 nm with the increase of rutin/lipid (R/L) ratios; however,
during the storage time all diﬀerent ratios tested maintained their
physical stability. Furthermore, the R/L ratios of 5% and 10% presented
good stability during the storage period and few amounts of rutin were
released. When incorporated in food models, NCLs have shown to be
stable during storage and processing time and they did not aﬀect the
appearance of the food models (Babazadeh, Ghanbarzadeh, &
Hamishehkar, 2016). Other authors encapsulated diﬀerent types of
terpenes in NLCs produced by ultrasound homogenization using mod-
iﬁed beeswax as solid lipid and caprylic triglyceride as liquid lipid.
They obtained NLCs with particle sizes around 97 nm and 106 nm with
ζ-potential values above −30mV, which demonstrate a good physical
stability for the diﬀerent types of terpenes. Relatively to the release
study, overall, it was observed a burst release in the ﬁrst hours and then
a gradual release. Furthermore, it has been observed that terpenes with
lower lipophilicity tend to remain linked to lipid nanoparticles for
longer time than higher lipophilic terpenes (Lasoń, Sikora, Ogonowski,
Tabaszewska, & Skoczylas, 2016).
To choose a suitable lipid blend, it is necessary to take into account
the following factors: i) solubility of the nutraceuticals in the lipid
matrices; ii) the solid and liquid lipids need to be miscible at speciﬁc
concentrations, but their molecules should be spatially incompatible
together; iii) the lipid phase should be stable to chemical degradation;
and iv) the lipid should have low toxicity and not produce toxic re-
sidues during the NLCs preparation. Medium Chain Triglycerides
(MCT), oleic acid and natural edible oils are the most used liquid oils
whereas the most used solid lipids are glycerides, fatty acids and waxes
(Dima et al., 2015). Similar to SLNs, NLCs could be prepared through
cold or hot homogenization. NLCs can be divided into three types: i)
imperfect type, in which NLCs are produced with solid and liquid lipids
chemically very diﬀerent from each other, resulting in systems with
imperfections or holes where the nutraceutical are accommodated in
molecular form; ii) amorphous type, in which the lipid core solidiﬁes in
amorphous state instead of crystalline state; and iii) multiple type,
where the solid lipid matrix has small liquid nano-compartments of oil
where the nutraceuticals are dissolved, increasing the loading capacity
and the possibility of controlled release (Tamjidi et al., 2013).
2.3.5. Self-dispersing lipid formulations (SDLF)
SDLFs are isotropic oil solutions or isotropic mixtures of oils, sur-
factants, co-surfactants and co-solvents. However, these systems are not
emulsions, they only transform in emulsions when in contact with
water or biological ﬂuids (Dima et al., 2015; Shin et al., 2015). The
principal advantage of this system is the improvement of nutraceuticals'
solubility in the GI tract which enhance their adsorption. SDLF bioa-
vailability depends on the digestion of lipids, lipophilicity of nu-
traceuticals, type of lipids and on the mean droplet diameter (Pathak &
Raghuvanshi, 2015). Monoglycerides are the most used oils and can
present diﬀerent self-assembly structures when in contact with water.
They can be dispersed in vesicles or liposomes structures for lamellar
phases, or in cubosomes (bicontinuous cubic particles) and hexosomes
(bicontinuous hexagonal particles) for cubic or hexagonal phases, re-
spectively. Their main applications in food products are the controlled
release of aroma, creation of ﬂavors compounds through Maillard re-
action and structure food products (Augustin & Hemar, 2009). One
disadvantage of these systems is the utilization of large amounts of
surfactants and their toxicological risks; however, there are not many
studies on this yet (Augustin & Hemar, 2009; Dima et al., 2015).
Quercetin has been encapsulated in self-emulsifying drug delivery
system (SEDDS) composed of Capmul MCM as the oil phase, Tween 20
as surfactant and ethanol as co-surfactant and its stability and anti-
oxidant capacity was evaluated. Emulsions with globule size of 77 nm,
polydispersity of 0.24 and ζ-potential value of −19.5 mV have been
obtained. The system did not show separation of phases or turbidity
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until after 6 months and showed robustness and stability for diﬀerent
dilutions and diﬀerent values of pH. Furthermore, SEDDS were stable
when subjected to freeze/thaw and accelerated stability tests. The de-
veloped SEDDS with quercetin showed similar antioxidant activity
when compared to free quercetin, showing that quercetin's properties
remained even in the presence of SEDDS components (Jain, Jain,
Pohekar, & Thanki, 2013).
2.3.6. Biopolymer-based delivery systems
Biopolymers (e.g. polysaccharides and proteins) can be used to
create a wide range of delivery systems for nutraceuticals, either in-
dividually or combined.
Polymeric particles can be produced with common food biopoly-
mers through self-assembly and can be used to encapsulate both hy-
drophilic and hydrophobic nutraceuticals. Their main advantages are
high loading eﬃciency, high stability, biocompatibility, biodegrad-
ability and controlled release (McClements et al., 2009; Shin et al.,
2015).
Polymeric micelles are formed above the critical micelle con-
centration of amphiphilic biopolymers which have both hydrophobic
and hydrophilic functional groups. These structures are constituted by a
hydrophilic region (shell) and a hydrophobic part (core). Their main
advantages are low toxicity, high loading capacity and improved water
solubility. The most used polymeric micelles for encapsulation of nu-
traceuticals are casein micelles (Shin et al., 2015). As an example,
docosahaxaenoic acid (DHA) has been bonded to casein and then, en-
trapped within re-assembled casein micelles. Casein micelles with a size
of 50 nm and 60 nm were obtained, which were not aﬀected by the
thermal treatment. Also, this system showed a remarkable protective
eﬀect against DHA oxidation, good colloidal stability and bioactive
conservation throughout shelf life (Zimet, Rosenberg, & Livney, 2011).
Biopolymer-derived hydrogels have also recently captured con-
siderable attention as promising delivery systems for nutraceuticals
(Abaee, Mohammadian, & Jafari, 2017). Hydrogels can be deﬁned as
networks of hydrophilic polymers formed by covalent and hydrogen
bonds, van der Waals interactions or physical entanglements. They are
able to absorb large amounts of water while maintaining their internal
network structure. These systems also have a high loading capacity for
nutraceuticals and targeted release ability, being suitable to be used as
delivery systems. In particular, nanohydrogels combine hydrogels'
properties (such as hydrophilicity and high water content) with those of
nanotechnology (i.e. very small sizes), exhibiting a unique potential as
nanoscale delivery systems (Mokhtari, Jafari, & Assadpour, 2017). Also,
nanohydrogels can be taken up by cells and may more easily access
some areas of body that are impossible for hydrogels. They can be
produced by physical self-assembly or chemical cross-linking of am-
phiphilic or hydrophilic polymers. The principal advantages of nano-
hydrogels are their high stability, high loading capacity, response ca-
pacity to environmental stimuli and high water content (McClements
et al., 2009; Shin et al., 2015). This type of system has also gained
considerable interest as a delivery system. Recently, curcumin and
caﬀeine have been incorporated in lactoferrin-glycomacropeptide na-
nohydrogels and their ability to encapsulate and release both lipophilic
and hydrophilic compounds was evaluated. The authors obtained na-
nohydrogels with sizes of 170 nm, 112 nm and 126 nm for empty na-
nohydrogels, nanohydrogels with curcumin and nanohydrogels with
caﬀeine, respectively. It was observed that nanohydrogels are capable
to encapsulate both lipophilic and hydrophilic compounds, with en-
capsulation eﬃciencies of 95% and 90% for curcumin and caﬀeine,
respectively. The release of these bioactive compounds was also eval-
uated at pH 2 and pH 7, and it was observed that the medium pH has a
signiﬁcant eﬀect on their release (Bourbon, Cerqueira, & Vicente,
2016).
Polysaccharide-protein complexes consist in the combination of two
or more biopolymers - polysaccharides and proteins - and can be de-
ﬁned as coacervates or precipitates. Coacervates are open structures
rich in water that can be formed when biopolymers have opposite net
charges and the complex's net charge does not oppose the higher-order
association. Precipitates are also formed by biopolymers with opposite
net charges, but in this case, are promoted when biopolymers interac-
tions are strong enough to release water and counter-ions.
One disadvantage of coacervates is their instability and tendency to
coalesce when subjected to diﬀerences of pH or ionic strength. The
stabilization of these structures can be promoted by adding glutar-
aldehyde or multivalent ions, heating treatment or enzymatic treatment
(McClements et al., 2009). It has been reported that nanocomplexes of
β-lactoglobulin and pectin encapsulating DHA present good stability
and particle size (between 110 nm and 272 nm), resulting in clear
suspensions appropriate for application in clear beverages. Moreover,
these complexes showed to be able to protect DHA from degradation
(Zimet & Livney, 2009).
2.3.7. Nanolaminated systems
Multilayers of diﬀerent materials can be assembled on top of pre-
existent delivery systems (e.g. emulsions, liposomes, polymeric parti-
cles), forming nanolaminated systems. Layer-by-layer (LbL) is the most
used method for producing nanolaminated systems and consists in the
adsorption of charged layers of polyelectrolytes on top of the core
material. The main advantages of LbL technique are the simplicity of
the process and equipment, capability of application in several sizes and
irregular shapes, with control of the size, composition, porosity, stabi-
lity, surface functionality and colloidal stability (McClements & Li,
2010). As the diﬀerent layers are connected together through electro-
static attraction, it is possible that these layers dissociate with the
change in pH or ionic strength. To ensure the connection between
layers, LbL systems may be subjected to heating, enzymatic and che-
mical treatments (McClements et al., 2009).
Multilayer emulsions can be produced by coating the nutraceuticals-
containing oil droplets with one or more charged layers. Their pro-
duction requires high control of pH, ionic strength, type and con-
centration of polyelectrolyte, emulsiﬁers and the sequence of com-
pound-adding. Some advantages of multilayer emulsions are the
capability to incorporate lipophilic and hydrophilic compounds, im-
provement of the solubility of lipophilic components, bioadhesive
properties, permeability through biological membranes, better physical
and chemical stability to environmental stresses, capacity to trigger the
release of the nutraceutical and control the release rate (Dima et al.,
2015; McClements et al., 2009). In fact, the incorporation of lactoferrin
in bi-layer nanoemulsions stabilized by WPI has been shown to improve
their environmental stability namely, pH changes and salt addition
(Teo, Lee, & Goh, 2017).
Multilayer nanocapsules can be produced using the LbL technique
followed by dissolution of a colloidal template in acid or solvent and
several centrifugation-washing cycles (Pinheiro et al., 2015). These
systems have the ability to protect and release the nutraceuticals in the
speciﬁc site of action (e.g. small intestine, colon). Recently, folic acid
has been incorporated in nanolaminates developed by the LbL deposi-
tion of alginate and chitosan, and it was observed that folic acid en-
trapped in nanolaminates was more stable under ultraviolet light ex-
posure than non-encapsulated folic acid. Also, the release proﬁles of
folic acid were aﬀected by pH conditions, showing a greater release at
pH 7 compared to pH 3, suggesting that the developed nanolaminates
might exhibit a controlled release in the GI tract (i.e. scarce release at
the stomach and a burst release in the small intestine) (Acevedo-Fani,
Soliva-Fortuny, & Martín-Belloso, 2018). Other authors developed a
multilayer coating based on κ-carrageenan and quercetin-loaded le-
cithin/chitosan nanoparticles by LbL technique (Souza et al., 2018).
This multilayer coating showed to have good antioxidant capacity and
did not present cytotoxicity.
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3. Gastrointestinal fate of delivery systems/nutraceuticals
Ingested delivery systems undergo a series of complex physico-
chemical and physiological processes as they pass through the diﬀerent
regions of the human GI tract, before the release of nutraceuticals
(Fig. 3).
3.1. Changes in delivery systems' properties in the GI tract
Mouth: Right after ingestion, delivery systems can experience
changes in their composition, structure and properties due to the
complex processes occurring within human mouth. In the oral phase,
delivery systems are mixed with saliva, being diluted and submitted to
a complex forces/ﬂow proﬁle. Also, there may be changes in their pH,
ionic strength and temperature; they can interact with the surface of the
tongue and mouth; they can be physically broken down into smaller
pieces by chewing and, depending on their composition, they may be
hydrolyzed by the digestive enzymes which, is the case of starch that is
hydrolyzed by amylase (McClements, 2014a). Therefore, the char-
acteristics of the delivery systems after exposure to oral conditions can
be very diﬀerent from the initial characteristics. For example, it has
been shown that nanoemulsions with diﬀerent lipid phase compositions
signiﬁcantly increased their particle size after passing through the
mouth phase (Zhang, Zhang, Kumosani et al., 2016). After this phase,
delivery systems are transformed in a form suitable for swallowing
(bolus) and pass down the esophagus, entering the stomach (Tso,
2000).
Stomach: Within the stomach, the delivery systems are submitted
to harsh physicochemical and physiological conditions that may further
change its composition and structure. In fact, the high acidity (i.e. pH
between 1 and 3) may cause the degradation of some of the components
within the colloidal delivery systems. Also, the alterations in pH and
ionic strength (that present high values around 100mM, being Na+,
K+, Ca2+ and Cl− the major species) may lead to changes in the
electrical characteristics of ionizable groups, and therefore in the
electrostatic interactions of the system, that could have direct con-
sequences in the integrity, permeability or aggregation of the colloidal
delivery systems. Moreover, the gastric enzymes may hydrolyze some
components of the delivery systems (i.e. gastric lipases initiate lipid
digestion, whereas gastric proteases begin protein digestion) and sur-
face-active substances (e.g. phospholipids and proteins) present in the
gastric juices may adsorb to the surfaces of the delivery systems, al-
tering their surface characteristics. Delivery systems are also submitted
to complex ﬂow/force patterns (i.e. gastric motility) that mix them with
the gastric juices, break down any remaining large fragments, as well as
transfer the digested material into the small intestine (McClements,
Decker, & Park, 2008). The type and composition of the delivery system
will inﬂuence the degree and nature of the changes that occur within
the stomach. For instance, it has been shown that protein-stabilized
nanoemulsions are prone to coalescence phenomena at some extent
within the stomach. However, higher instability was observed for
multilayer nanoemulsions (stabilized by a protein and a poly-
saccharide) that exhibited a large increase in the particle size (in-
dicative of an extensive droplet aggregation) and a high evidence of
creaming (Pinheiro, Coimbra, & Vicente, 2016). Other authors also
conﬁrmed that the delivery systems behavior under gastric conditions is
highly inﬂuenced by their composition: surfactant-stabilized emulsions
have shown to be stable within the gastric environment, whereas the
protein-stabilized emulsions exhibited extensive ﬂocculation, leading to
creaming (van Aken, Bomhof, Zoet, Verbeek, & Oosterveld, 2011).
Small intestine: The partially digested material that leaves the
stomach and enters the small intestine is usually referred to as “chyme”.
The chyme is mixed with small intestine ﬂuids: i) sodium bicarbonate is
secreted to increase pH from highly acidic to closer to neutral (typically
within the range of pH 5.4 to 7.4), in order to favor the pancreatic
enzymes activity; ii) bile salts and phospholipids (surface active com-
pounds) are secreted to facilitate emulsiﬁcation of the lipids by ad-
sorbing to the droplet surfaces; iii) pancreatic enzymes are secreted to
further digest any macronutrients remaining within the chyme (pro-
teins are converted to peptides/amino acids by proteases, triacylgly-
cerols are converted to monoacylglycerols/free fatty acids by lipases,
and starches are converted into oligosaccharides/glucose by amylases),
and iv) co-lipase is secreted in order to achieve the optimum lipase
activity (McClements et al., 2008). In addition to sodium bicarbonate,
other salts are secreted into the small intestine, being the ionic strength
around 140mM (Lindahl, Ungell, Knutson, & Lennernäs, 1997), which
inﬂuences the magnitude and range of any electrostatic interactions
occurring in the delivery system. Small intestine is considered the main
site for nutraceuticals' absorption. In particular, lipophilic compounds'
solubilization, transport and absorption is enhanced by the mixed mi-
celles' formation that transport the solubilized components through the
mucus layer until they reach the surfaces of the enterocytes where they
are absorbed (van Aken, 2010). The behavior of the delivery systems
Fig. 3. Physiological and physicochemical changes of delivery systems that can
occur within the human gastrointestinal tract (adapted from (Pinheiro,
Gonçalves, Madalena, & Vicente, 2017)).
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during intestinal digestion is dependent on their composition. It has
been shown that the emulsiﬁer charge used to produce nanoemulsions
has a signiﬁcant eﬀect on their size, charge and microstructure during
digestion (in particular at duodenum, jejunum and ileum stages), con-
sequently, inﬂuencing the free fatty acids release and nutraceuticals'
bioavailability (Pinheiro et al., 2013).
Colon: Only a fraction of the components reaches the colon, once
the majority of the ingested food is broken down and absorbed in the
upper GI tract (i.e. stomach and small intestine). Therefore, only de-
livery systems composed of indigestible components (e.g. indigestible
oil or dietary ﬁbers) are expected to reach the colon without being
absorbed (McClements, 2014a). Colon has a near neutral pH and con-
tains a wide range of viable bacteria. In fact, as many as 400 species of
bacteria can be found there, being the predominant species Bacteroides,
Biﬁdobacterium and Eubacterium (Sinha & Kumria, 2003). These bacteria
are able of breaking down various food components that are not di-
gested in the upper gut (Basit, 2005). It is clear that the colon complex
microbial ecosystem has a signiﬁcant impact in nutraceuticals' bioa-
vailability. For example, it has been demonstrated that the mutual re-
lationship between microbiota and phenolic compounds increases the
phenolic compounds' bioavailability and provides increased health
beneﬁts (Ozdal et al., 2016). The main fermentation products (pro-
duced by the digestive enzymes released from colonic bacteria) of
carbohydrates and proteins in the colon are short chain fatty acids that
may be beneﬁcial to human health (Sinha & Kumria, 2003). In addition,
colon bacteria are able to metabolize protein-based nutraceuticals
(Tozaki et al., 1997).
3.2. Mechanisms of nutraceuticals' release
Diﬀerent physicochemical mechanisms can be involved in the re-
lease of nutraceuticals from the matrix surrounding it and, depending
on the system and environmental conditions, a diﬀerent mechanism
may prevail. The release can be classiﬁed into the following types:
i) Diﬀusion-controlled release: It is the most important mechanism
used to control the nutraceuticals' release. The release rate of the
nutraceutical depends on the size, shape, structure and composition
of the delivery system, and is driven by the concentration gradient
between the interior of the particle and the surrounding medium
(Crank, 1975).
ii) Swelling-controlled release: When immersed in liquid media,
hydrophilic polymers gradually start to hydrate, causing relaxation
of the polymer chain with consequent volume expansion – swelling
– and the nutraceutical can diﬀuse out (Berens & Hopfenberg,
1978). In this case, the nutraceuticals' release rate is controlled by
the water diﬀusion rate and by the polymers' chain relaxation rate
(Peppas, Bures, Leobandung, & Ichikawa, 2000).
iii) Erosion-controlled release: The nutraceutical is released from the
matrix by erosion of its outer layer, for example by physical, che-
mical or enzymatic degradation. The release rate depends on the
erosion rate, which is inﬂuenced by the composition and structure
of the outer layers of the matrix and by the magnitude and duration
of the factor that causes erosion (e.g. shear force, pH and enzymes)
(McClements, 2012a).
iv) Fragmentation-controlled release: The nutraceutical is released
when the matrix material is physically, chemically or enzymatically
disrupted. In this case, the release rate will depend on the stress
applied to cause the fracture, as well as on the size and shape of the
fragments formed (McClements, 2012a).
v) Dissolution-controlled release: The nutraceutical is released from
the delivery system as a result of a dissolution process when the
delivery system is exposed to speciﬁc environmental conditions.
The release rate is governed by the dissolution rate, which depends
on the composition and structure of the delivery system, as well as
on the magnitude and duration of the environmental factor that
causes dissolution (e.g. dilution, solvent type, pH, ionic strength or
temperature) (McClements, 2014b).
vi) Stimuli-controlled release: The release of nutraceuticals is acti-
vated by internal or external stimuli such as temperature
(Fundueanu, Constantin, Ascenzi, & Simionescu, 2010), pH
(Fuciños et al., 2014) or ionic strength (Bawa, Pillay, Choonara, &
Toit, 2009).
3.3. Absorption of delivery systems/nutraceuticals
As previously mentioned, small intestine is considered the main site
for delivery systems/nutraceuticals absorption. The intestinal wall is a
complex and active structure that guarantees intestinal equilibrium by
regulating nutrient absorption, interactions between intestinal micro-
ﬂora and immune system (Davitt & Lavelle, 2015). Before reaching the
endothelia cells, nutraceuticals or delivery systems must ﬁrst diﬀuse
through the thick intestinal mucus layer. This mucus layer is synthe-
sized by goblet cells and it is composed by a combination of glyco-
proteins and lipids (Boegh & Nielsen, 2015). Diﬀerent properties in-
ﬂuence the ability to pass through the mucus layer such as size, charge
and viscosity (Lai, Wang, & Hanes, 2009). Permeability of large mole-
cules or mucoadhesive lipophilic compounds may be reduced when
interacting with mucus. Nutraceuticals may have limited capacity to
permeate the gut endothelia. However, lipophilic compounds, such as
resveratrol and kaempferol, mixed with phospholipids, free fatty acids
and bile salts may pass through the intestinal mucus (Gleeson, Ryan, &
Brayden, 2016). On the other hand, nutraceuticals entrapped in na-
nostructures coated with polymers such as polyethylene glycol (PEG),
chitosan, lectin and gelatin, can pass through or adhere to the mucus
layer allowing nutraceuticals' uptake (Mansuri, Kesharwani, Jain,
Tekade, & Jain, 2016). Nano-delivery systems with negative surface
charges can be repelled by the mucus layer, decreasing the residence
time in the epithelial cells, thus lowering cellular uptake (Hariharan
et al., 2006). It has been reported that positively charged poly(lactic-co-
glycolic acid) (PLGA) nanoparticles loaded with estradiol had an in-
creased cellular uptake compared to negatively and neutrally charged
nanoparticles (Hariharan et al., 2006).
After diﬀusion through the mucus, two major routes may be con-
sidered when nutraceuticals or nano-delivery systems cross the in-
testinal epithelium barrier, namely paracellular (through tight junc-
tions) and transcellular (including M-cell-mediated transport) routes.
3.3.1. Paracellular route
Paracellular route is responsible for passive transport of molecules
through intercellular spaces between intestinal epithelial cells
(Daugherty & Mrsny, 1999). Intestinal permeability is regulated by
epithelial tight junctions (TJ), which are a complex structure composed
by diﬀerent proteins such as occludin and claudin, positioned at the
intercellular space (Lerner & Matthias, 2015). They are necessary to
maintain intercellular adhesion, to regulate paracellular transport, to
limit the access of microbes to host tissues, and to mediate the mole-
cules' passage from the lumen to the lamina propria (Bischoﬀ et al.,
2014). TJ allow the passage of small hydrophilic and polar molecules
(e.g. water, ions, sugars, peptides and amino acids) with a molecular
weight lower than 500 Da (Maher, Mrsny, & Brayden, 2016). It has
been reported that certain compounds increase TJ functionality (such
as polyphenols) while other compounds (such as caprylic fatty acid)
reduce TJ barrier function, enhancing uptake of other small molecules
(Bohn et al., 2015). Paracellular transport possibly reduces intracellular
metabolism, which is relevant for nutraceuticals. However, a previous
study has demonstrated that polyphenols, including caﬀeic acid, quer-
cetin, chrysin, gallic acid, resveratrol and rutin are poorly transported
via the passive diﬀusion pathway in both Caco-2 cells and parallel ar-
tiﬁcial membrane permeability assay (Rastogi & Jana, 2014). On the
other hand, the passage of nano-delivery systems across the intestinal
epithelium using the paracellular route is very limited because TJ
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cannot open more than 20 nm; thus, this space is constricted for a
majority of nano-delivery systems (Yu, Yang, Zhu, Guo, & Gan, 2016).
Nano-delivery systems with size lower than 20 nm may reversibly dis-
turb TJ and release the nutraceuticals to blood. Afterwards, TJ function
returns to their regular position (Li, Jiang, Xu, & Gu, 2015). Moreover,
due to the negative charge present at the membrane surface, it has been
shown that positive nanoparticles can be easily transported by the
paracellular route (Park, Chang, & Hoboken, 2011; Yu et al., 2013).
Nano-delivery systems containing the cationic compound chitosan have
thus the ability to open TJ, enhancing paracellular transport (Chen
et al., 2013). For instance, poly(glycolic acid) (PGA) and chitosan-based
nanoparticles as carriers of tea catechins have been reported to cross
the intestinal barrier via paracellular transport mechanism (Tang et al.,
2013).
3.3.2. Transcellular route
The transcellular route consists on the transport (passive or active)
of molecules through cells by endocytosis. Most nutraceuticals are
known for being absorbed by simple transcellular route – passive
transport – without requiring receptors or carriers (Renukuntla,
Vadlapudi, Patel, Boddu, & Mitra, 2013). Transcellular passive diﬀusion
has been proposed for carotenoids and apolar polyphenol aglycones
(Bohn et al., 2015). For example, SLNs loaded with curcumin permeate
through Caco-2 cells using the passive diﬀusion mechanism (Guri,
Gülseren, & Corredig, 2013).
In contrast, there is another mechanism, which involves expenditure
of metabolic energy - active transport. Some biomolecules (e.g. polar or
charged molecules) bind to a speciﬁc naturally-occurring membrane-
protein transporter (carrier-mediated transport) or receptor (receptor-
mediated transport), located in the apical cell membrane, and they are
transported within the intestinal cell against concentration gradient
(Yun, Cho, & Park, 2013), otherwise they could not diﬀuse across the
cell membrane (Park et al 2011). These membrane carriers and re-
ceptors are important to the uptake of many nutraceuticals. For in-
stance, vitamin C, fatty acids and some peptides are carried on by so-
dium vitamin C co-transporter, fatty acid-binding proteins, and proton
coupled peptide transporter, respectively (Gleeson et al., 2016). Also,
many polyphenols present the capacity of inhibiting or stimulating
membrane transporters, which depend on the polyphenol form, con-
centration, exposure time, etc. (Bohn et al., 2015).
Molecules that bind to speciﬁc cell membrane receptors or carriers
at the apical cell membrane are internalized in the cell by endocytic
processes, which include phagocytosis or pinocytosis (Kettiger,
Schipanski, Wick, & Huwyler, 2013). Phagocytosis is mainly restricted
to the M-cells of the Peyer's patch (M-cells mediated transport) (des
Rieux et al., 2007). These cells, specialized in antigen sampling, oﬀer an
alleged route to nano-delivery systems (Yun et al., 2013). Once M-cells
represent less than 1% of total intestine area, the transport via these
cells is very diﬃcult to occur (Acosta, 2009). Nano-delivery systems
could also be internalized by pinocytosis, a mechanism that allows in-
ternalize extracellular molecules through the binding to com-
plementary cell surface receptors (e.g. lactoferrin, lectins and α5β1
integrin) (Plapied, Duhem, des Rieux, & Préat, 2011). Some nano-de-
livery systems have been using a receptor-speciﬁc ligand on their sur-
face to achieve or enhance speciﬁc intracellular delivery of nu-
traceuticals, in both enterocytes and M-cells (Zhang & Wu, 2014). For
instance, lactoferrin nanoparticles containing gambogic acid were
transported through cell membrane due to the presence of lactoferrin
receptor (Zhang et al., 2013). It is also important to mention that some
nutraceuticals are transported back into the lumen of the GI tract by
eﬄux transporters present in the phospholipid bilayers, after absorp-
tion by epithelium cells. Thus, the uptake of certain nutraceuticals into
the systemic circulation could be limited (Misaka, Müller, & Fromm,
2013).
Therefore, the understanding of the diﬀerent transport mechanisms
across GI tract is essential for the development of eﬀective
nutraceuticals' nano-delivery systems.
3.4. Degradation/metabolism/retention of nutraceuticals in the body
Nutraceuticals may be metabolized by diﬀerent enzymes or undergo
chemical degradation (e.g. hydrolysis and oxidation) during their pas-
sage through the GI tract before reaching epithelium cells. For example,
bioactive proteins or peptides may be hydrolyzed in the stomach due to
the presence of proteases and low pH, and fatty acids are targeted by
pancreatic lipases (Davitt & Lavelle, 2015). In contrast, metabolism can
be useful for some nutraceuticals to be absorbed into the systemic cir-
culation. It has been reported that quercetin glycoside (quercetin-4′-O-
glucoside) is absorbed in the small intestinal through a sodium-glucose
transporter and hydrolyzed by intracellular β-glucosidases, after which
it passively diﬀuses across the basolateral membrane (Lotito, Zhang,
Yang, Crozier, & Frei, 2011). However, nutraceuticals' bioavailability
and activity may be limited due to metabolism within the GI tract. An
example is curcumin that undergoes a series of metabolic reactions due
to pH variations in the GI tract resulting in a variety of metabolites with
diﬀerent properties (McClements, Zou et al., 2015). Also, the metabolic
activity of intestinal microbiota on nutraceuticals can change host ex-
posure to these compounds and their potential health eﬀects. Moreover,
colon constitutes a metabolism active site rather than a simple excre-
tion route (Laparra & Sanz, 2010). Following absorption, nutraceuticals
may be distributed via portal blood or via lymphatic system to liver and
spleen (Griﬃn et al., 2016). For example, resveratrol is rapidly meta-
bolized in the liver and intestine, resulting in a low oral bioavailability.
Thus, delivery systems may be a good approach to protect and stabilize
nutraceuticals from chemical transformations and metabolism until
they are released near the site of absorption. For instance, delivery
systems at nano-scale are generally more abundant in kidney, liver and
spleen as compared with larger-sized systems, which stay inside the GI
tract (Piperigkou et al., 2016). When nano-delivery systems pass the GI
barrier and go to the systemic blood circulation, they are distributed
throughout the body, accessing cells and organelles that internalize and
retain these structures. Some of the potential consequences of cellular
interactions are cytotoxicity, inﬂammation, oxidative stress, and gen-
otoxic eﬀects (Rossi et al., 2014). The accumulation of delivery systems
composed of proteins and polysaccharides would be improbable be-
cause they are digested in the stomach, small intestine or colon.
However, transformations and retention of delivery systems in the body
are strictly related to their physicochemical properties; thus, a case-by-
case approach for evaluating eﬃcacy and safety is required.
4. Oral bioavailability of nutraceuticals
Bioavailability is dependent on digestion, release from food matrix,
absorption by intestinal cells, and transport to the target body cell. Only
the nutraceutical fraction that reaches the blood in an active form is
distributed to the organs and tissues where it can exert its beneﬁcial
health eﬀects.
4.1. Factors inﬂuencing oral bioavailability
In order to develop a successful strategy to improve the bioavail-
ability of a nutraceutical, the main factors limiting its bioavailability
have to be established. The following equation summarizes the major
factors inﬂuencing the bioavailability (BA) of a nutraceutical
(McClements, Li et al., 2015):
= × ×
∗ ∗ ∗BA B A T (2)
Where B∗ is the fraction of the nutraceutical that is bioaccessible
(i.e. potentially available for absorption (Etcheverry, Grusak, & Fleige,
2012)), A∗ is the fraction of the bioaccessible nutraceutical that is ab-
sorbed through the layer of epithelial cells, and T∗ is the fraction of the
absorbed nutraceutical that reaches the site of action in a metabolically
R.F.S. Gonçalves et al. Trends in Food Science & Technology 78 (2018) 270–291
280
active form. In vivo nutraceuticals' bioavailability is typically de-
termined by measuring the area under the curve (AUC) (concentration
vs. time) in the blood following the ingestion of a known amount of
nutraceutical, compared to the AUC in the blood following intravenous
injection of the same amount of nutraceutical (Joye, Davidov-Pardo, &
McClements, 2014).
The use of classiﬁcation schemes to characterize nutraceuticals in
terms of the factors that limit their bioavailability may lead to a faster
identiﬁcation of the appropriate delivery strategies to increase their
bioavailability. According to the ‘‘Biopharmaceutical Classiﬁcation
System’’ (BCS) there are four classes of nutraceuticals: class I — high
solubility and permeability compounds; class II — low solubility and
high permeability compounds; class III—high solubility and low per-
meability compounds; and class IV—low solubility and permeability
compounds (Amidon, Lennernäs, Shah, & Crison, 1995). Other scheme
has been recently developed to characterize the major factors limiting
the nutraceuticals bioavailability in food - Nutraceutical Bioavailability
Classiﬁcation Scheme (NuBACS) (McClements, Li et al., 2015). Ac-
cording to this scheme, the bioavailability limiting factors can be di-
vided into the following categories: bioaccessibility (B*); absorption
(A*); and transformation (T*), being each one of these categories di-
vided in sub-categories in order to describe the precise mechanism in-
volved. The sub-categories for B* are: poor liberation from the food
matrix (L), poor solubility in the GI ﬂuids (S) and interactions that
promote insolubility (I); for A*, the sub-categories are: poor transport
through the mucus layer (ML), through the TJ, or through the bilayer
membrane (BP), the inhibition of active transporters (AT), or the pre-
sence of eﬄux transporters (ET) in the epithelium cells; and for T*, the
sub-categories are: changes in bioactivity is due to chemical degrada-
tion (C) or metabolism (M). Also, each category is ﬂowed by the symbol
“(+)” when it is a non-limiting factor and “(−)” when it is a limiting
factor (McClements et al., 2016)). Table 3 presents a brief overview of
the application of both BCS and NuBACS systems to various nu-
traceuticals.
Also, there are several other physicochemical/physiological pro-
cesses that may contribute to nutraceuticals low bioavailability such as
the limited release from food matrix and the formation of insoluble
complexes with other compounds in the GI tract (Arora & Jaglan,
2016).
4.2. Emerging strategies for improving nutraceuticals' bioavailability
Some of the strategies that have emerged to overcome the limited
bioavailability of most nutraceuticals are discussed below.
4.2.1. Delivery systems' optimization
The speciﬁc design of colloidal delivery systems is an eﬃcient way
to improve nutraceuticals' dispersibility, stability, food compatibility
and bioavailability. In fact, bioavailability is known to depend on de-
livery systems' composition, size and interfacial properties, and so these
properties can be optimized to develop eﬀective delivery systems
(McClements, 2015b). Diﬀerent approaches could be used such as
particle size reduction of the delivery system, incorporation of speciﬁc
ingredients in the delivery systems' formulation known to increase the
absorption of encapsulated nutraceuticals, or co-ingestion of nu-
traceuticals and excipient foods.
4.2.1.1. Nano-based formulations. An eﬀective approach to improve the
oral bioavailability of nutraceuticals is to use delivery systems at the
nanoscale, due to the increase of the surface-to-volume ratio by
reducing particle size into the nano-range (Faridi Esfanjani & Jafari,
2016). The use of nano-delivery systems could facilitate the entry of the
nutraceutical through biological barriers, while avoiding the metabolic
modiﬁcations that lead to low absorption (Rein et al., 2013).
In recent years, diﬀerent nano-delivery systems have been shown to
boost bioavailability and eﬃcacy of nutraceuticals. Parthasarathi et al.
(2016) evaluated the eﬀect of droplet size on oral vitamin E emulsions
bioavailability and observed that nanoemulsions with a size of 277 nm
showed a 3-fold increase in the AUC when compared to conventional
emulsions (Parthasarathi et al., 2016). Evaluating the inﬂuence of
particle size on β-carotene bioaccessibility, other authors have shown
that β-carotene bioaccessibility increases with decreasing droplet dia-
meter (small > medium > large) (Salvia-Trujillo, Qian, Martín-
Belloso, & McClements, 2013). In another study, hydroxycitric acid
(HCA) has been nanoencapsulated using SLNs. The authors observed
that HCA-loaded nanoparticles exhibited a 2-fold higher bioavailability
than non-encapsulated HCA and a 1.3-fold higher bioavailability com-
pared to microparticles due to smaller particle size, longer residence
time and HCA controlled release (Ezhilarasi, Muthukumar, &
Anandharamakrishnan, 2016). In order to enhance curcumin absorp-
tion by oral administration, liposome-encapsulated curcumin has been
developed (Takahashi, Uechi, Takara, Asikin, & Wada, 2009). Results
have shown a 5-fold increase in bioavailability of liposome-en-
capsulated curcumin compared to suspension (based on AUC). Other
authors have showed that the bioavailability of coenzyme Q10 in-
creased 5-fold after administration of the micellar NanoSolve for-
mulation (Lipoid GmbH, Ludwigshafen, Germany), and the bioavail-
ability of vitamin E was enhanced 10-fold, both compared to the pure
substances (Wajda, Zirkel, & Schaﬀer, 2007).
4.2.1.2. Mucus diﬀusion enhancers and absorption enhancers. The
incorporation of speciﬁc compounds in the delivery systems
formulation is another alternative to enhance the absorption of
nutraceuticals. This can be achieved in two ways: by improving
mucus diﬀusion of lipophilic compounds using mucolytic agents, or
by improving their permeability using absorption enhancers (Gleeson
et al., 2016).
Mucolytic agents or mucus diﬀusion enhancers have the ability to
cleave mucoglycoprotein substructures responsible for the mucus layer
viscoelastic and adhesive properties, facilitating the penetration of
compounds to the underlying absorptive endothelial cells (Müller et al.,
2012). Therefore, they hold the potential to increase intestinal
Table 3
Selected examples of nutraceuticals' classiﬁcation according to BCS (Shin et al.,
2015) and NuBACS (McClements, Li & Xiao, 2015) systems.
Nutraceutical Potential Health Beneﬁts Class
BCS NuBACS
β-carotene Antioxidant
Anti-aging
Preventing heart disease
IV B*(−)L,I,S
A*(−)TJ,AT,ET
T*(−)C
Curcumin Anti-inﬂammatory
Antioxidant
Anticancer
IV B*(−)L,S
A*(−)TJ,AT,ET
T*(−)M,C
Quercetin Lower blood lipid
Anti-inﬂammatory
Antioxidant
IV B*(−)L
A*(−)BP,ET
T*(−)M
Resveratrol Decrease LDL and increase HDL
Antioxidant
Anticancer
II B*(−)S
A*(−)ET
T*(−)M,G
EGCG Antioxidant, Antitumor
Anti-inﬂammatory
III B∗(−)L,S
A∗(−)TJ,AT,ET
T∗(−)M,C
BCS - Biopharmaceutical Classiﬁcation System; NuBACS - Nutraceutical
Bioavailability Classiﬁcation Scheme; LDL-low-density lipoprotein cholesterol;
HDL high-density lipoprotein cholesterol; EGCG (−)-epigallocatechin-3-gallate;
B*- bioaccessibility; A*- absorption; T*- transformation; L-poor liberation from
the food matrix; S- poor solubility in the gastrointestinal ﬂuids; I- interactions
that promote insolubility; TJ-poor transport through the mucus layer through
the tight junctions, BP- poor transport through the bilayer membrane; AT-in-
hibition of active transporters, ET-presence of eﬄux transporters in the epi-
thelium cells; C- changes in bioactivity due to chemical degradation; M-changes
in bioactivity due to metabolism; + non-limiting factor; − limiting factor.
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absorption of nutraceuticals that are unable to penetrate the small in-
testinal mucus layer. N-acetylcysteine (NAC) (Yuan et al., 2015) and
mucolytic enzymes such as bromelain and papain (Pereira de Sousa
et al., 2015) are some examples of compounds that can be used as
mucolytic agents.
Absorption enhancers, also termed permeation or bioavailability
enhancers, are functional agents included in formulations to improve
the absorption of a bioactive compound, usually by enhancing mem-
brane permeation (Aungst, 2012). Compounds such as bile salts, sur-
factants, fatty acids, chelating agents, salicylates, polymers and herbal
bioactives have shown to be eﬀective in improving the intestinal ab-
sorption of diﬀerent nutraceuticals (Kesarwani & Gupta, 2013). They
can act either paracellularly by the opening of TJ or, in most cases,
transcellularly by increasing plasma membrane permeability, or a
combination of both (Maher et al., 2016). For example, chitosan in-
creases the absorption via the paracellular route by redistribution of the
cytoskeletal F-actin, causing the opening of the TJ, whereas bile salts
and fatty acids increase the absorption by improving hydrophobic
bioactive compounds' solubility in the aqueous layer or by increasing
the ﬂuidity of apical and basolateral membranes (Kesarwani & Gupta,
2013).
Although several absorption enhancers have been successful used by
the pharmaceutical industry for development of formulations for drugs
that have poor membrane permeation, most of them could cause
membrane perturbation to varying extents. The majority of these da-
mages are rapidly repairable; however, it is still unknown if the re-
peated dosing of some absorption enhancers for chronic therapy can
cause irreversible epithelial damage (McCartney, Gleeson, & Brayden,
2016). In order to reduce the risk of toxicity, permeation enhancers
should reversibly disturb the intestinal barrier ideally without being
absorbed, should be pharmacologically inert, have excipient or GRAS
status, and have a history of safe use in humans (Gleeson et al., 2016).
The use of bio-based permeation enhancers could be a safe and eﬃcient
alternative (Kesarwani & Gupta, 2013). Table 4 shows examples of
absorption enhancers that can be used in food formulations (GRAS
status or of food origin) to promote nutraceuticals intestinal absorption.
4.2.2. Food matrix design: excipient foods
As an alternative to the incorporation of nutraceuticals in delivery
systems, nutraceuticals may be delivered as part of food matrices, that
can be divided into two major classes: functional foods and excipient
foods (McClements, 2015a). Functional foods contain nutraceuticals
trapped within the food matrix, whereas an excipient food can be de-
ﬁned as a component that may not exhibit bioactivity itself, but it may
increase the eﬃcacy of nutraceuticals that are co-ingested with it
(McClements & Xiao, 2014). In particular, excipient foods have gained
much attention in the last years. In this case, nutraceuticals might be
left in their natural source (e.g. fruit or vegetable) and their bioavail-
ability can be boosted by consuming them with excipient foods, spe-
ciﬁcally formulated to control their release, solubilization, transport,
metabolism and absorption within the GI tract (McClements, 2015a).
When designing an excipient food, diﬀerent factors must be con-
sidered: i) the composition and structure of the food matrix should be
speciﬁcally designed to allow an increase in the bioavailability of co-
ingested nutraceuticals, ii) the excipient food should have good sen-
sorial attributes, iii) a food matrix that can be consumed in a regular
basis with foods containing nutraceuticals must be chosen, iv) the ex-
cipient food should have a suﬃciently long shelf-life and be easy to
storage (McClements & Xiao, 2014). Salad dressings, sauces, yogurts,
creams, ice-creams, butter and margarine are some examples of po-
tential excipient foods. O/W emulsions are particularly suitable can-
didates for developing excipient foods due to the great ﬂexibility in
their design (e.g. ability to incorporate hydrophilic, amphiphilic and
lipophilic ingredients, being their composition and structure easily al-
tered), easy preparation, high physical stability, rapid GI digestibility
and due to the fact that they are already used in food and beverage
products (McClements et al., 2016).
The potential of emulsion-based excipient systems in enhancing the
lipophilic nutraceuticals' bioavailability in fruits and vegetables has
been highlighted in several works. However, it has been also showed
that excipient emulsions' eﬃcacy to increase nutraceuticals bioavail-
ability depends on diﬀerent factors such as nutraceutical itself, lipid
phase, emulsiﬁer type, emulsions' size or thermal treatment. The in-
ﬂuence of the initial droplet size on the ability of excipient emulsions to
increase carotenoid bioaccessibility from carrots has been investigated
(Zhang, Zhang, Zou et al., 2016). Authors shown that carotenoid
bioaccessibility signiﬁcantly increased with the decrease of lipid dro-
plet size in the excipient emulsions, being this result attributed to the
rapid formation of mixed micelles that solubilize the carotenoids in the
intestinal ﬂuids.
In another work, the use of excipient emulsions with diﬀerent
droplet sizes to increase the lycopene bioaccessibility in tomato juice
has been evaluated (Salvia-Trujillo & McClements, 2016). Lycopene
bioaccessibility increased from 7.5% (emulsion-free samples) to 12.5%
and 10% for emulsions containing small and large droplets, respec-
tively. The authors attributed this relatively modest increase in bioac-
cessibility to the high level of lycopene entrapment within the chro-
moplasts, which remained intact during in vitro digestion, thus
preventing the transfer of lycopene into the mixed micelles.
Other authors developed zein nanoparticles encapsulating curcumin
to obtain a high loading capacity and good chemical stability. They
mixed these nanoparticles with digestible lipid nanoparticles developed
to increase curcumin bioaccessibility. It has been concluded that de-
livery systems containing mixed colloidal particles (i.e. protein and
lipid nanoparticles) are able to increase the lipophilic bioactive com-
pounds' bioaccessibility (Zou et al., 2016).
These examples show that nutraceuticals' bioavailability can be in-
creased by the addition of digestible lipids that form mixed micelles
after digestion, and solubilize nutraceuticals within intestinal ﬂuids.
This strategy can be applied to nutraceuticals whose bioavailability is
low due to their limited release from the food matrix and their limited
solubility in intestinal ﬂuids (i.e. B*(−)L,S compounds). In the case of
nutraceuticals whose bioavailability is low due to other factors, such as
GI transformation or poor absorption (i.e. A*(−) compounds), one of
the strategies that could be adopted is the design of excipient foods
formulated with food grade components that increase cell permeability
or reduce eﬄux mechanisms, such as piperine (Kesarwani & Gupta,
2013) or sucrose esters (Szűts & Szabó-Révész, 2012).
Although excipient food technology could be used to create new
food products speciﬁcally developed to enhance nutraceuticals' bioa-
vailability in natural products, it is also important to evaluate the safety
of these products before their widespread application. In fact there are
some concerns that must be addressed: i) besides increasing the nu-
traceutical bioavailability, the excipient food may also enhance the
bioavailability of any toxic agents present in a food product; ii) by in-
creasing the nutraceutical bioavailability, the excipient food may
change its toxicity proﬁle; iii) the alteration of the barrier properties of
cell membranes may promote dysfunction of the intestinal barrier and
iv) the nature of the gut microbiota could also be altered by changing
the nutraceuticals' type and concentration reaching the colon
(McClements et al., 2016).
5. Evaluation of bioaccessibility and bioavailability of
nutraceuticals within nano-delivery systems
Delivery systems for nutraceuticals, such as nano-delivery systems,
are promising structures to overcome the limitations of nutraceuticals
after oral intake (e.g. poor aqueous solubility and poor oral bioavail-
ability) (Acosta, 2009). Consequently, new nano-based approaches
emerged and demonstrated their potential to enhance nutraceuticals'
bioavailability. Several in vitro and in vivo studies have been conducted
to assess the bioaccessibility and bioavailability of nutraceuticals within
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nano-delivery systems. Therefore, these topics related with nano-de-
livery systems will be described and discussed below.
5.1. In vitro
In the light of major concerns of nutraceutical nano-based for-
mulations related to their bioavailability and stability during the di-
gestive process, several in vitro studies, ranging from measurements of
bioaccessibility to the studies of uptake in cell culture models, have
been proposed. Distinct in vitro model systems are described below.
5.1.1. Artiﬁcial in vitro gastrointestinal systems
The bioaccessibility of a nutraceutical is determined by measuring
the quantity of ingested dose (with intact structure) reaching the ab-
sorption site. To verify the bioaccessibility of a nutraceutical, numerous
in vitro models can be used to simulate GI tract environment (Ting,
Zhao, Xia, & Huang, 2015). In fact, in vitromodels generally diﬀer in the
inclusion of diﬀerent stages of digestion (i.e. mouth, gastric, small in-
testinal and large intestinal); digestion times; concentrations of elec-
trolytes; bile acids' pH; digestive enzymes involved and peristalsis
motion. In vitro models can be static (i.e. with preﬁxed concentrations
and volumes of digested materials, enzymes, salts, etc.) or dynamic (i.e.
mimic the continuous changes of the physicochemical conditions)
(Kostewicz et al., 2014). The pH-stat model is an example of a static
model which simulates the digestion environment in the small intestine.
This model is an especially appropriate apparatus to assess the change
in bioaccessibility of hydrophobic compounds (Kostewicz et al., 2014).
For digestion of nano-delivery systems, a multiple-step technique is
normally used to model the physicochemical transformations which
these systems undergo as they pass from an organ to the other (e.g.
stomach to intestine) in the GI tract (Alger, Momcilovic, Carlander, &
Duncan, 2014). For instance, a digestion model involving the in vitro
simulation of stomach, duodenum, jejunum and ileum has been used to
evaluate the digestion of curcumin nanoemulsions (Pinheiro et al.,
2013) and β-lactoglobulin nanohydrogels containing riboﬂavin
(Madalena et al., 2016). However, static models cannot reproduce the
in vivo physical conditions including the GI tract peristalsis motion,
integration of all of the inﬂuential physiological factors, transitional
change in the physiological environment, and elimination from the
absorption site. Dynamic models simulating the GI digestion include
more complex and precise models for nutraceuticals' bioaccessibility
estimation, which is the case of the dynamic TNO gastro-Intestinal
Model (TIM-1) (Sjögren et al., 2014). This continuous in vitro model
oﬀers control of physiological parameters that simulates relevant as-
pects of digestion (e.g. peristalsis motion, gastric and intestinal re-
sidence time). Also, bioaccessible fraction can be sampled continuously
from jejunum and ileum segments at programmed times. As a result,
intestinal bioaccessibility of compounds in diﬀerent types of formula-
tions can be investigated (Ting et al., 2015). Bourbon et al. (2016)
evaluated the digestibility of chitosan-coated lactoferrin-glycomacro-
peptide (Lf-GMP) nanohydrogels using a dynamic in vitro system. These
authors observed that chitosan improved the stability of Lf and GMP
(i.e. these proteins were hydrolyzed at a slower rate) and maintained
their structure intact for longer period of time (Bourbon et al., 2016).
5.1.2. Intestinal epithelial monolayer assays (cellular uptake)
To further investigate the transport of nano-delivery systems
through the natural barriers of the GI surface, a variety of in vitro ap-
proaches are available (Shahbazi & Santos, 2013). In vitro cell lines
(monocultures), such as Caco-2 and HT-29 have been frequently used
(Gamboa & Leong, 2013) due to its similar morphology (i.e. organized
brush borders, functional TJ between adjacent cells, enzymes, nuclear
receptors and transporters expressed in membrane) with intestinal
human epithelial cells, known as enterocytes (Song et al., 2013). Caco-2
(human colon carcinoma) cell line is grown normally as a monolayer on
polycarbonate membrane in transwell chambers. In this system, the
apical and basolateral culture ﬂuids are separated allowing the trans-
port of molecules from one culture ﬂuid to the other (Liu et al., 2016).
This model is useful to quantify compound absorption across the
monolayer, determine apparent permeability coeﬃcient (Papp) and
analyze uptake mechanisms (e.g. absorption or diﬀusion). When using
in vitro cell lines that simulate intestinal epithelium, motorization of
transepithelial electrical resistance (TEER) and ﬂuorescent marker
transport (e.g. ﬂuorescein) during transport assay are common methods
to assure the integrity of the monolayers (Lorkowski, 2012). Recently,
Caco-2 cell line was used to explore transport mechanisms of two dif-
ferent structures: polymeric PLGA nanoparticles (He et al., 2013) and
curcumin loaded-folic acid/soy protein nanoparticles (Teng, Luo,
Wang, Zhang, & Wang, 2013). In another study, (−)-epigallocatechin-
3-gallate (EGCG) in ovoalbumin-dextran conjugate nanoparticles
showed higher Papp on Caco-2 monolayers compared to free EGCG in
solution (Li & Gu, 2014). As for HT29 cells (being the clone HT29-H of
particular interest), this speciﬁc cell line has the ability of producing
mucus (Schimpel et al., 2014), a variable that is mostly neglected in
other in vitro based-cell models. Mucus is crucial to properly study
transport mechanisms, mainly because its presence can hamper the
diﬀusion of nano-delivery systems before they can reach intestinal cells
(Guri et al., 2013; Plapied et al., 2011). Also, it is known that specia-
lized M-cells are involved in nano-delivery systems' transport; in order
to mimic this feature, human Raji B lymphocyte cells are being co-
cultured with other cell lines (e.g. Caco-2 cells), once these cells exhibit
B cell markers that induced the reconstruction of M cells (des Rieux
et al., 2007).
It is important to highlight that the successful prediction of nu-
traceuticals and nano-delivery systems absorption highly depend on the
ability of in vitro models in simulating the characteristics of the in vivo
intestinal epithelium. Thus, in order to overcome the individual lim-
itations of each cell type, and to accurately predict the transport me-
chanism of nano-delivery systems, in vitro models integrating diﬀerent
cell types (co-cultures) are being used (Antunes, Andrade, Araújo,
Ferreira, & Sarmento, 2013; Schimpel et al., 2014). Examples are the
co-culture of Caco-2 and HT29-MTX cells to assess the transport route
of curcumin-solid lipid nanoparticles (Guri et al., 2013), and a triple co-
culture Caco-2/HT29/Raji B cells with the aim of developing a more
accurate in vitro model of the intestinal epithelial layer (Lopes et al.,
2016). An overview of the in vitro cellular uptake studies is given in
Table 5.
5.2. In vivo
In vitro models or a combination of models to predict the eﬃcacy of
nano-delivery systems are valuable tools to study the factors that im-
pact nutraceuticals bioaccessibility and bioavailability. Still, the com-
plex simulation of pre-absorption (e.g. TIM-1 system) and absorption
(e.g. Caco-2 and HT29-MTX co-culture) using in vitro models cannot
entirely reproduce and predict the oral bioavailability due to lack of
biological factors, such as systemic metabolism and volume of body
distribution (Gamboa & Leong, 2013).
Many research studies implemented in vivomodels to investigate the
beneﬁcial eﬀects of nutraceuticals or pharmacokinetics of nano-de-
livery systems. In vivo pharmacokinetic studies, are considered the best
procedure to predict human oral bioavailability although they are time-
consuming, costly and there are often ethical constrains involved. In
vivo animal models (e.g. mouse, rat, sheep and pig) present all the
physiological and physiochemical events during the absorption, dis-
tribution, metabolism and elimination (ADME) of ingested nano-de-
livery systems and nutraceuticals. Some in vivo studies investigated
body distribution of nano-delivery systems or nutraceuticals following
oral delivery using diverse detection techniques. Determination of nu-
traceuticals and their metabolites in the animal blood, tissues, urine or
the enzymes levels may provide data of its bioavailability (Gamboa &
Leong, 2013). The use of radio and stable isotopic techniques for some
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nutraceuticals or nano-delivery systems allows the examination of its
route, tissue distribution and bioavailability. Sonaje et al. (2012) stu-
died the biodistribution of isotope-labelled insulin loaded chitosan/poly
(γ-glutamic acid) nanoparticles following the oral administration using
microscopic and computed-tomographic approaches. The in vivo results
indicated that insulin could be absorbed into the systemic circulation,
being most of chitosan retained in the microvilli scaﬀolds (Sonaje et al.,
2012).
In general, nano-delivery systems are retained in the GI tract with
some distribution reported in the liver, bladder, kidney and lymph
nodes. ADME of orally administered nanomaterials is inﬂuenced by
their characteristics such as shape, size, hydrophobility, surface charge,
and functionalized groups (Griﬃn et al., 2016). Selected in vivo studies
are reported in Table 5. However, in vivo pharmacokinetic data pub-
lished are rarely comparable since animal models, dose, formulation,
and delivery system are selected without harmony.
5.3. In situ and ex vivo
In situ and ex vivomodels are also widely used to replicate the in vivo
situation, once they allow a more accurate prediction of compounds'
absorption comparing to in vitro models.
In situ experiments include intestinal loop, intestinal perfusion and
intestinal vascular cannulation models. They typically refer to experi-
ments on whole animals, providing intact intestinal mucosa, complete
blood supply and nerve domination, together with expression of en-
zymes and transporters (Liu et al., 2016). However, sophisticated sur-
gical procedures and instrumentation are required. In these methods,
the compounds' absorption can be directly measured by the dis-
appearance of the absorbed compound from the gut or indirectly
measured by the rate of compounds' appearance in plasma, excretion in
urine, or by the speed of onset or degree of pharmacologic action (Luo
et al., 2013). For example, in situ intestinal perfusion method has been
used to study the potential enhancement of curcumin's intestinal ab-
sorption and oral bioavailability via taurocholic acid-modiﬁed NLCs. It
has been demonstrated that the addition of taurocholic acid to the NLCs
boosted curcumin absorption. In fact, depending on the degree of
modiﬁcation, curcumin taurocholic acid-modiﬁed NLCs displayed
about 5–15-fold higher area under the curve in rats after oral admin-
istration compared to unmodiﬁed curcumin NLCs (Tian et al., 2017).
Ussing chamber and everted intestinal sac methods are the most
common examples of ex vivo studies. They are advantageous methods
because the cell-cell contact remain intact, all cell types remain present,
being enzyme systems, co-factors and transporters present in their
physiological context (Esther, Inge, & Geny, 2007). However, they
present some drawbacks such as interruption of the normal blood ﬂow
and lack of a nervous system, which sometimes lead to an inappropriate
estimation of oral absorption degree (Luo et al., 2013). Despite that, ex
vivo methods are simple and widely used in the design and testing of
encapsulated nutraceuticals. For example, nanoparticles based on
quaternary ammonium–chitosan conjugate have been tested as vehicles
for antioxidants contained in red grape seeds extracts, being the Ussing
chamber the method applied to study the nanoparticles' penetration
across intestinal barrier. The nanoparticles have been found to migrate
from the donor to the acceptor compartment and penetrate across ex-
cised rat intestine from mucosal to serosal side in an integral state,
showing great potential as proﬁtable vehicles for oral administration of
antioxidants extracts (Fabiano et al., 2016).
6. Safety evaluation of nano-delivery systems
The great potential of nano-based formulations for food applications
introduced serious concerns about their toxicity. This concern is mainly
based on their increased surface-to-volume ratio compared to their
micro-sized counterparts. Potential in vitro and in vivo eﬀects of nano-
based formulations cannot be anticipated from a previous knowledge of
bulk analogs. So, it is essential to consider relevant parameters to study
toxicity (Lai, 2012). As a starting point to toxicity assessment, it is
fundamental to characterize the nanostructure itself. For example, de-
termine its materials, structure, size, shape, surface area, charge, so-
lubility, hydrophobicity, stability and aggregation state (Podila &
Brown, 2013). There are numerous studies of toxicity measurement in
various cellular and animal models using diﬀerent techniques. A se-
lection of in vitro and in vivo toxicity evaluation using nano-delivery
systems as carriers of nutraceuticals is summarized in Table 6.
Toxicity tests are mainly focused on in vitro toxicity analysis, which
includes cellular uptake and localization studies (using microscopy
methods), cellular viability assays (cellular proliferation, necrosis and
apoptosis), and mechanistic assays measuring DNA damage and oxi-
dative stress (Arora, Rajwade, & Paknikar, 2012). These assays are
generally used once they are easy, eﬃcient and low cost. The limita-
tions of these assays are the fact of the results can vary depending on
the type of assay and nano-based formulations used (e.g. dose con-
centration), and consequently could not predict in vivo toxicity (Arora
et al., 2012). In vivo toxicity assays are normally conducted in rat and
mouse models. These models oﬀer an opportunity to study nanoma-
terial acute and chronic dose-response, biodistribution, retention, ex-
cretion, and other eﬀects. The most used animal toxicity measurements
comprise tissue morphology, changes in cell population, blood serum
chemistry, weight change, and longevity. Nevertheless, it is funda-
mental to consider other variables such as dose concentration, and
targeted tissues or organs. Even though rat and mouse models could be
used to analyze a complete organism, some caution have to be con-
sidered when extrapolating toxicity results for human consumption. In
addition, biodistribution quantiﬁcation frequently needs ﬂuorescent or
radiologic labels, which may alter the clearance route. Currently, there
are no standardized protocols available for particular nanomaterials,
which led to numerous studies with diﬀerent preparation methods,
materials, cell lines, doses, etc. making diﬃcult to compare results.
Many of the recently developed nano-delivery systems can increase
the transport of poorly hydrophilic compounds across the GI barrier by
enhancing paracellular transport through TJ opening. Certain nano-
delivery systems' components such as surfactants, polymers, chelating
agents, may increase the gap dimensions and consequently perme-
ability (Maher et al., 2016). The use of selected enhancers that alter
barrier integrity or permeability could induce toxicity, even though
many compounds could be considered GRAS, due to the continuous
perturbation of the intestinal epithelia through mild detergent-based
surfactant eﬀects (Chassaing et al., 2015). Also, selected enhancers
could stimulate permeability to inﬂammatory molecules (such as al-
lergens, toxins and bacteria) which damage colonic epithelium and
consequently, may lead to intestinal inﬂammation diseases such as in-
ﬂammatory bowel disease (Maher et al., 2016). Therefore, the ab-
sorption enhancer action should be reversible (i.e. damage quickly re-
paired) and their action should be rapid, coinciding with the presence
of the nutraceutical at the absorption site.
Many components in nano-delivery systems, such as antibody
fragments, peptides, proteins, can act as antigens, resulting in increased
immunotoxicity. Additionally, consumers could take high amounts of
nano-delivery systems containing surfactants that may cause adverse
eﬀects in the body (Renukuntla et al., 2013). Clinical trials could be
used to assess the short-term nano-delivery systems' toxicity, as well as
long-term toxicity because chronic exposure and accumulation could be
a serious problem (Elsaesser & Howard, 2012). Biodegradable nano-
delivery systems can be degraded or digested in GI tract. Nutraceuticals
encapsulated within those nano-delivery systems could be also ab-
sorbed; however, their characteristics, structure and pharmacokinetic
may be changed. If the objective is to decrease toxicity and adverse
eﬀects of nano-delivery systems, target ligants could be used in their
surface to targeted speciﬁc cells (Ciappellano, Tedesco, Venturini, &
Benetti, 2016). If the nutraceutical is incorporated into a food product
that is consumed in a regular basis and in large quantities (for example,
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beverages), this is very important. Presently, there is a lack of guide-
lines and standardized safety tests variables established to determine
toxicity and adverse eﬀects of nano-delivery systems (Garduño-
Balderas, Urrutia-Ortega, Medina-Reyes, & Chirino, 2015). Being so, as
previously mentioned, their safety concerns should be explored and
food safety studies should be conducted about ADME and toxicological
characteristics.
7. Future trends and conclusions
The incorporation of nutraceuticals into food products provides a
simple way of developing a variety of functional foods that could help
fulﬁlling some of the consumers' health and wellness needs. However,
the nutraceuticals' eﬀectiveness depends on preserving their bioavail-
ability. Delivery systems can be speciﬁcally designed to modulate
bioaccessibility, absorption, or transformation proﬁle of nutraceuticals
in the GI tract, boosting their bioavailability and consequently, their
health beneﬁts. Progress is being made by transferring the knowledge
from pharmaceutical applications, including the use of nano-delivery
systems, absorption enhancers or excipient foods that have been shown
to improve solubility, stability or permeability of nutraceuticals.
However, there are still some challenges that must be overcome, that
include: i) the exclusive use of food-grade ingredients, ii) development
of delivery systems stable in food matrices along processing and shelf-
life, iii) diﬃculty to control the release of nutraceuticals, iv) optimi-
zation of delivery systems formulations in order to increase the per-
meability through the intestinal walls, v) potential toxicity of absorp-
tion enhancers due to perturbation of the intestinal epithelia even for
agents with GRAS status, and vi) in the case of nano-delivery systems,
the risk assessment of their use of in food. This latter issue is particu-
larly relevant, once, although the absorption of intact food grade de-
livery systems into the systemic circulation is unlikely due to changes
after undergone gastric and intestinal digestion, reliable data regarding
the risks of nano-delivery systems cannot be found in the literature and
also, from the existent studies, it is not possible to predict the con-
sequences of their long-term intake. Therefore, in order to evaluate
their safety, more realistic in vitro digestive models need to be designed
to undoubtedly understand the fate of micro and nano-delivery sys-
tems/nutraceuticals in the GI tract; more advanced analytical methods
to accurately detect and quantify nano-delivery systems must be de-
veloped; and a clear legislation and guidelines concerning their impact
on human health and on environment must be assured. Also, in order to
develop delivery systems with increased functionality, more eﬀorts
should be made towards understanding the interactions between the
delivery systems and the food matrix. Future studies should focus on
improving the physicochemical characteristics of the delivery systems,
by the careful selection of the delivery systems' formulation on a case-
by-case basis.
The development of delivery systems that aﬀord nutraceuticals'
greatest functionality and safety may create opportunities to apply
enabling technologies such as nanotechnology more broadly in the food
industry.
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